Crizotinib is an inhibitor of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and c-MET, binding competitively to the ATP-binding pocket of kinases. Crizotinib exhibits anticancer chemotherapeutic benefit in the treatment of non-small cell lung cancer (NSCLC) and is currently in clinical trials as a potential treatment for neuroblastoma and other advanced solid tumors. In cellular models, this compound upregulates expression of pro-apoptotic BIM and downregulates expression of anti-apoptotic survivin to induce apoptosis and inhibit cell proliferation.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.